Abbott Laboratories $ABT Stock: Crescent Grove Advisors LLC Grows Position

Crescent Grove Advisors LLC lifted its position in shares of Abbott Laboratories (NYSE:ABT) by 377.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 18,641 shares of the healthcare product maker’s stock after buying an additional 14,738 shares during the period. Crescent Grove Advisors LLC’s holdings in Abbott Laboratories were worth $1,842,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. raised its position in Abbott Laboratories by 4.6% in the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after purchasing an additional 6,769,518 shares during the period. State Street Corp increased its stake in Abbott Laboratories by 1.7% in the 2nd quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker’s stock worth $7,343,246,000 after purchasing an additional 1,350,766 shares during the period. Bank of America Corp DE purchased a new stake in shares of Abbott Laboratories during the second quarter valued at approximately $1,603,607,000. Deutsche Bank AG boosted its position in Abbott Laboratories by 18.6% during the 2nd quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker’s stock valued at $1,515,963,000 after buying an additional 2,614,965 shares during the period. Finally, Legal & General Group Plc purchased a new position in shares of Abbott Laboratories in the second quarter valued at about $1,082,524,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Down 1.8%

Abbott Laboratories stock opened at $100.59 on Thursday. The business has a 50-day simple moving average of $105.47 and a two-hundred day simple moving average of $98.28. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $132.02. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The company has a market cap of $174.06 billion, a P/E ratio of 32.55, a P/E/G ratio of 1.90 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, hitting the consensus estimate of $1.42. The firm had revenue of $13.01 billion during the quarter, compared to analyst estimates of $12.99 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%. Abbott Laboratories’s revenue was up 14.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.30 EPS. Analysts predict that Abbott Laboratories will post 5.53 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Third-quarter adjusted earnings per share were $1.42, in line with the company’s consensus estimate, while revenue rose 14.5% year over year to $13.01 billion, slightly exceeding expectations. Comparable sales increased 7%, and Abbott reaffirmed its full-year adjusted EPS guidance. Abbott third-quarter results
• Positive Sentiment: Management announced plans to separate its approximately $8.5 billion Nutrition business—including Ensure, Similac, Glucerna, Pedialyte and PediaSure—into an independent, publicly traded company through a tax-free distribution to shareholders, targeted for completion by the end of 2027. Abbott believes the transaction could accelerate growth and expand margins in its remaining businesses. Abbott Nutrition separation announcement
• Positive Sentiment: New product approvals and European authorization for Abbott’s Cologuard Plus colorectal cancer test expand its diagnostics portfolio and could support longer-term growth. Cologuard Plus European approval
• Neutral Sentiment: The spin-off is intended to unlock value by allowing Abbott and the new Nutrition company to pursue separate strategies, but investors must assess execution, tax and transition risks before the separation is completed.
• Negative Sentiment: Abbott lowered its 2026 sales-growth forecast, citing weakness in medical devices. The reduced outlook suggests near-term operating momentum may be softer than previously expected, despite continued strength in areas such as continuous glucose monitoring. Reuters report on Abbott’s outlook
• Negative Sentiment: Some analysts characterized the $1.42 adjusted EPS result as a slight miss against a $1.43 estimate. Combined with the lower sales outlook and uncertainty surrounding the Nutrition separation, that has outweighed the quarter’s revenue growth and caused the stock to decrease.

Analysts Set New Price Targets

Several research firms have weighed in on ABT. Wolfe Research upgraded Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective for the company in a report on Thursday, August 13th. BTIG Research raised their target price on Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a research note on Friday, July 17th. Piper Sandler reiterated an “overweight” rating and issued a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. UBS Group decreased their target price on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Finally, Citigroup increased their target price on Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.88.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.